Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (21)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2022

  1. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

    Scientific Reports, Vol. 7

  3. Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction

    American Journal of Cardiology, Vol. 119, Núm. 12, pp. 2042-2048

2016

  1. Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population

    PLoS ONE, Vol. 11, Núm. 12

  2. Understanding the Role of CCN Matricellular Proteins in Myocardial Fibrosis

    Journal of the American College of Cardiology

2015

  1. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study

    Free Radical Biology and Medicine, Vol. 81, pp. 1-12

  2. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

  2. Osteopontin-mediated myocardial fibrosis in heart failure: A role for lysyl oxidase?

    Cardiovascular Research, Vol. 99, Núm. 1, pp. 111-120

  3. The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

    Cardiovascular Diabetology, Vol. 12, Núm. 1

2012

  1. GLP-1 and cardioprotection: From bench to bedside

    Cardiovascular Research, Vol. 94, Núm. 2, pp. 316-323

2011

  1. Aspectos emergentes del sistema renina-angiotensina en la diabetes: ¿cómo abordar su traslación a la clínica?

    Revista Espanola de Cardiologia Suplementos, Vol. 11, Núm. SUPPL. 4, pp. 37-41

  2. Aspectos emergentes del sistema renina-angiotensina en la diabetes: ¿cómo abordar su traslación a la clínica?

    Revista Espanola de Cardiologia Suplementos, Vol. 11, Núm. 4, pp. 37-41

2009

  1. Genomics and proteomics in heart failure research

    Revista Espanola de Cardiologia

2007

  1. Progress in hypertensive heart disease. Remodeling mechanisms involved in the transition from hypertrophy to heart failure

    Revista Espanola de Cardiologia Suplementos, Vol. 7, Núm. F

2006

  1. Alteraciones del metabolismo del colágeno fibrilar en la cardiopatía hipertensiva. Situación actual y perspectivas

    Revista Espanola de Cardiologia, Vol. 59, Núm. 10, pp. 1047-1057